On October 20, 2026 Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, and Labcorp (NYSE: LH), a global leader in innovative and comprehensive laboratory services, reported they have entered into a definitive agreement for Myriad to sell its Prenatal Health testing business, which includes the Prequel, Foresight, SneakPeek, and FirstGene tests, to Labcorp for $210 million in cash, plus the value of the inventory of the Prenatal Health testing business at closing.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"This announcement is the direct outcome of our disciplined strategic review process, which is focused on sharpening our portfolio, enhancing operational execution, and driving shareholder value," said Sam Raha, President and CEO, Myriad Genetics. "This transaction is expected to be accretive to Myriad’s revenue growth and profitability, while meaningfully strengthening the balance sheet to support continued investment in our strategic priorities tied to the cancer care continuum and long-term value creation. Working closely with Labcorp, one of the nation’s largest laboratory service providers, we expect a smooth transition that preserves uninterrupted patient access to our prenatal tests."
When complete, the transaction is expected to provide more patients and physicians with expanded access to Labcorp’s comprehensive, high-quality laboratory services, convenient patient service center network, robust data analytics and digital tools.
"This transaction supports Labcorp’s specialty testing growth strategy," said Bryan Vaughn, Executive Vice President and President of Diagnostics, Labcorp. "Myriad Genetics has built a highly complementary reproductive genetics platform, supported by innovative screening solutions and deep scientific expertise. By combining these capabilities with Labcorp’s operational strength and high-quality women’s health portfolio, we aim to improve outcomes, expand access to advanced screening solutions and enhance the patient and provider experience."
Labcorp expects the transaction to add approximately $160 million in revenue in year one, to be slightly accretive to adjusted earnings in year one, and to reach average diagnostics segment margins by end of year two, once fully integrated.
Over the last twelve months, Myriad’s Prenatal Health testing portfolio has been used by thousands of providers and over 600,000 patients. Myriad plans to provide further commentary regarding this transaction, and other related organizational changes, on its third quarter earnings call on November 4, 2026.
The deal is subject to regulatory clearance and customary closing conditions, and the transaction is expected to close by early 2027.
Guggenheim Securities, LLC is acting as exclusive financial advisor, and Covington & Burlington LLP is acting as legal advisor to Myriad Genetics.
Barclays is acting as financial advisor, and Polsinelli is acting as legal advisor to Labcorp.
(Press release, Myriad Genetics, OCT 20, 2026, View Source [SID1234673607])